semaglutide and mash Semaglutide's Efficacy in Phase 3 Trial Wegovy (semaglutide 2.4 mg) approved

If pancreatitis is suspected, discontinue semaglutide immediately

RJVA-001 is a GLP-1 pancreatic gene therapy developed by Fractyl Health for the treatment of obesity and type 2 diabetes (T2D)

The GSH precursor NAC has been used as a treatment modality in numerous pulmonary ailments including chronic obstructive pulmonary disease (COPD) and chronic bronchitis

As a ghrelin receptor agonist, it also increases hunger

The HRS9531-203 clinical trial is a multicentre, randomised, double-blind, placebo-parallel-controlled, Phase 2 trial (NCT06054698) conducted by Hengrui Pharma in China to evaluate the efficacy and safety of the 8 mg dose of HRS9531 injection in adults (ages 18-65) with overweight or obesity (BMI 24-40 kg/m2) without type 2 diabetes